司馬尼布
![]() | |
臨床資料 | |
---|---|
ATC碼 |
|
識別資訊 | |
| |
CAS號 | 194413-58-6 ![]() |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C15H14N2O |
摩爾質量 | 238.29 g·mol−1 |
3D模型(JSmol) | |
| |
|
司馬尼布(INN:semaxanib;開發代號:SU5416)[1]是一種有機化合物,化學式為C15H14N2O。它可以2,4-二甲基吡咯為原料,經維爾斯邁爾-哈克反應轉化為醛,再和羥吲哚縮合製得:[2][3][4]
參考文獻
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85. WHO Drug Information. 2001, 15 (2). Full text (PDF). (原始內容 (PDF)存檔於2007-03-16). (244 KiB)
- ^ Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Journal of Medicinal Chemistry. July 1998, 41 (14): 2588–2603. PMID 9651163. doi:10.1021/jm980123i.
- ^ Lubkoll J, Millemaggi A, Perry A, Taylor RJ. Tandem Horner–Wadsworth–Emmons/Heck procedures for the preparation of 3-alkenyl-oxindoles: The synthesis of Semaxanib and GW441756. Tetrahedron. 2010, 66 (33): 6606–6612. doi:10.1016/j.tet.2010.03.018.
- ^ Blanche EA, Maskell L, Colucci MA, Whatmore JL, Moody CJ. Synthesis of potential prodrug systems for reductive activation. Prodrugs for anti-angiogenic isoflavones and VEGF receptor tyrosine kinase inhibitory oxindoles. Tetrahedron. 2009, 65 (25): 4894–4903. doi:10.1016/j.tet.2009.04.014.
|